About Supriya Lifescience Limited
Data last updated: 14 July 2026
Supriya Lifescience Limited is a public limited company based in Mumbai, Maharashtra, India. It specialises in api manufacturers, a part of the broader pharmaceuticals sector. Incorporated on 26 March 2008, the company has been in operation for over 18 years.
Registered with ROC Mumbai under CIN L51900MH2008PLC180452. Listed on BSE: 543434 and NSE: SUPRIYA.
Capital: an authorised share capital of ₹35 Cr and a paid-up capital of ₹16.1 Cr. It is led by directors including Smita Satish Wagh and Neelam Yashpal Arora.
Last AGM: 24 September 2025. Financial statements filed for year ended 31 March 2025. Office: 207/208 Udyog Bhavan Sonawala Road Goregaon (East), Mumbai, Maharashtra, India – 400063.
As per NSE-filed standalone financials for FY 2026, the company reported a revenue of ₹827.88 Cr, a growth of 18.86% compared to the previous year. The net worth stands at ₹1,197.73 Cr (up 20.16% YoY). Total assets are valued at ₹1,357.11 Cr (up 22.01% YoY).
The company has a workforce of approximately 450 employees as per the latest available data.
The company is associated with 1 brand - Supriya Lifescience. As per MCA filings, the company has open charges of ₹262.41 Cr and satisfied charges of ₹169.96 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website supriyalifescience.com.
-
EmailLocked
-
TelephoneLocked
-
Website
-
Social Media
-
Registered Address207/208 Udyog Bhavan Sonawala Road Goregaon (East), Mumbai, Maharashtra, India – 400063
-
IndustryPharma, API Manufacturers
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Supriya Lifescience Limited
Supriya Lifescience Limited has one previous CIN (Corporate Identification Number): U51900MH2008PLC180452. The current CIN is L51900MH2008PLC180452, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L51900MH2008PLC180452 | Current |
| U51900MH2008PLC180452 | Previous |
Associated Brands with Supriya Lifescience Limited
Supriya Lifescience Limited operates one associated brand: Supriya Lifescience. These brands represent Supriya Lifescience Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Active pharmaceutical ingredients and intermediates are manufactured. | supriyalifescience.com |
Business Activity of Supriya Lifescience Limited
Supriya Lifescience Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | Locked |
Business activity turnover details for Supriya Lifescience Limited
Turnover contribution percentages and historical activity changes require an active report plan.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Auditor Details of Supriya Lifescience Limited
Supriya Lifescience Limited is audited by Kakaria & Associates LLP (ICAI peer reviewed, certificate valid till 2027-03-31) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.
| Name | Financial year | Audit opinion |
|---|---|---|
| Kakaria & Associates LLP (ICAI peer reviewed, certificate valid till 2027-03-31) | FY 2026 | Declaration of unmodified opinion |
Board of Directors of Supriya Lifescience Limited
Supriya Lifescience Limited is currently managed by 10 directors, with 16 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Smita Satish Wagh
Also directs:
Supriya Lifescience Limited, Supriya Medi-Chem Private Limited
|
Whole-Time Director | 26 Mar 2008 | 18 Years 4 Months | Current |
|
Neelam Yashpal Arora
Also directs:
Supriya Lifescience Limited, Kesar Petroproducts Limited, Shreyas Intermediates Limited and 1 more
|
Director | 25 Mar 2021 | 5 Years 4 Months | Current |
|
Balasaheb Gulabrao Sawant
Also directs:
Supriya Lifescience Limited
|
Whole-Time Director | 26 May 2023 | 3 Years 2 Months | Current |
|
Satish Waman Wagh
Also directs:
Supriya Lifescience Limited, Supriya Medi-Chem Private Limited, Sachin Industries Limited and 4 more
|
Whole-Time Director | 26 Mar 2008 | 18 Years 4 Months | Current |
|
Saloni Satish Wagh
Also directs:
Supriya Lifescience Limited
|
Managing Director | 01 Jul 2022 | 4 Years 1 Months | Current |
|
Shivani Satish Wagh
Also directs:
Supriya Lifescience Limited
|
Managing Director | 01 Jul 2022 | 4 Years 1 Months | Current |
Financials of Supriya Lifescience Limited FY 2026 filings available
Supriya Lifescience Limited reported revenue of ₹827.88 Cr (up 18.86% YoY) for FY 2026.
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Revenue from Operations | ₹827.88 Cr | ₹696.49 Cr | ₹570.37 Cr | ₹460.94 Cr | ₹530.05 Cr |
| Other Income | ₹11.49 Cr | ₹9.82 Cr | ₹10.64 Cr | ₹9.49 Cr | ₹7.58 Cr |
| Total Income | ₹839.36 Cr | ₹706.3 Cr | ₹581.01 Cr | ₹470.43 Cr | ₹537.63 Cr |
| Cost of Materials Consumed | ₹265.12 Cr | ₹232.44 Cr | ₹191.43 Cr | ₹187.32 Cr | ₹198.83 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | -₹11.09 Cr | -₹21.26 Cr | ₹30.31 Cr | -₹6.51 Cr | -₹3.03 Cr |
| Employee Benefit Expense | ₹96.68 Cr | ₹80.52 Cr | ₹67.64 Cr | ₹55.58 Cr | ₹49.08 Cr |
| Finance Costs | ₹1.89 Cr | ₹1.69 Cr | ₹2.11 Cr | ₹3.08 Cr | ₹4.2 Cr |
| Depreciation & Amortisation | ₹28.41 Cr | ₹20.44 Cr | ₹15.81 Cr | ₹11.82 Cr | ₹10.12 Cr |
| Other Expenses | ₹183.12 Cr | ₹143.99 Cr | ₹108.02 Cr | ₹95.65 Cr | ₹71.18 Cr |
| Total Expenses | ₹564.13 Cr | ₹457.82 Cr | ₹415.32 Cr | ₹346.94 Cr | ₹330.38 Cr |
| Profit Before Exceptional Items & Tax | ₹275.24 Cr | ₹248.48 Cr | ₹165.69 Cr | ₹123.49 Cr | ₹207.25 Cr |
| Exceptional Items | -₹45.8 Lakh | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹274.78 Cr | ₹248.48 Cr | ₹165.69 Cr | ₹123.49 Cr | ₹207.25 Cr |
| Total Tax Expense | ₹65.66 Cr | ₹60.52 Cr | ₹46.58 Cr | ₹33.63 Cr | ₹55.44 Cr |
| Net Profit | ₹209.12 Cr | ₹187.96 Cr | ₹119.11 Cr | ₹89.86 Cr | ₹151.81 Cr |
| Other Comprehensive Income | -₹9.9 Lakh | -₹12.5 Lakh | ₹1.62 Cr | -₹1.26 Cr | -₹31.5 Lakh |
| Total Comprehensive Income | ₹209.02 Cr | ₹187.83 Cr | ₹120.74 Cr | ₹88.6 Cr | ₹151.5 Cr |
| EBITDA (computed) | ₹305.54 Cr | ₹270.61 Cr | ₹183.61 Cr | ₹138.39 Cr | ₹221.56 Cr |
| Basic EPS | ₹25.98 | ₹23.35 | ₹14.80 | ₹11.16 | ₹18.86 |
| Diluted EPS | ₹25.98 | ₹23.35 | ₹14.80 | ₹11.16 | ₹18.86 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total Assets | ₹1,357.11 Cr | ₹1,112.31 Cr | ₹921.24 Cr | ₹820.28 Cr |
| Non-current Assets | ₹824.8 Cr | ₹675.28 Cr | ₹523.43 Cr | ₹355.39 Cr |
| Current Assets | ₹532.3 Cr | ₹437.04 Cr | ₹397.8 Cr | ₹464.89 Cr |
| Property, Plant & Equipment | ₹683.32 Cr | ₹451.48 Cr | ₹303.7 Cr | ₹255.12 Cr |
| Inventories | ₹159.6 Cr | ₹118.35 Cr | ₹85.25 Cr | ₹115.77 Cr |
| Trade Receivables | ₹219.45 Cr | ₹134.36 Cr | ₹111.68 Cr | ₹84.66 Cr |
| Cash & Equivalents | ₹37.55 Cr | ₹76.06 Cr | ₹68.35 Cr | ₹85.25 Cr |
| Equity (Net Worth) | ₹1,197.73 Cr | ₹996.76 Cr | ₹815.37 Cr | ₹699.46 Cr |
| Equity Share Capital | ₹16.1 Cr | ₹16.1 Cr | ₹16.1 Cr | ₹16.1 Cr |
| Borrowings (Non-current) | ₹0 | ₹0 | ₹0 | ₹0 |
| Borrowings (Current) | ₹0 | ₹0 | ₹0 | ₹16.63 Cr |
| Total Debt (computed) | ₹0 | ₹0 | ₹0 | ₹16.63 Cr |
| Current Liabilities | ₹121.04 Cr | ₹82.16 Cr | ₹76.89 Cr | ₹95.78 Cr |
| Total Liabilities | ₹159.37 Cr | ₹115.55 Cr | ₹105.87 Cr | ₹120.82 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | ₹185.77 Cr | ₹164.68 Cr | ₹113.31 Cr | ₹66.19 Cr | ₹48.8 Cr |
| Investing Cash Flow | -₹176.17 Cr | -₹152.25 Cr | -₹173.58 Cr | -₹133.1 Cr | -₹59.82 Cr |
| Financing Cash Flow | -₹9.88 Cr | -₹8.23 Cr | -₹22.36 Cr | -₹3.37 Cr | ₹149.65 Cr |
| Capital Expenditure | ₹152.24 Cr | ₹162.38 Cr | ₹145.66 Cr | ₹108.4 Cr | ₹59.9 Cr |
| Free Cash Flow (computed) | ₹33.53 Cr | ₹2.3 Cr | -₹32.35 Cr | -₹42.21 Cr | -₹11.1 Cr |
| Dividends Paid | ₹8.05 Cr | ₹6.44 Cr | ₹4.83 Cr | ₹4.83 Cr | ₹4.39 Cr |
| Net Change in Cash | -₹28.7 Lakh | ₹4.2 Cr | -₹82.63 Cr | -₹70.28 Cr | ₹138.63 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹276.53 Cr | ₹206.44 Cr | ₹199.83 Cr | ₹145.07 Cr | ₹184.11 Cr | ₹185.65 Cr | ₹166.1 Cr | ₹160.63 Cr | ₹158.18 Cr | ₹140.07 Cr | ₹140.1 Cr | ₹132.02 Cr |
| Other Income | ₹3.48 Cr | ₹2.61 Cr | ₹2.73 Cr | ₹2.67 Cr | ₹2.98 Cr | ₹2.1 Cr | ₹2.52 Cr | ₹2.22 Cr | ₹2.19 Cr | ₹3.07 Cr | ₹2.47 Cr | ₹2.92 Cr |
| Total Income | ₹280.01 Cr | ₹209.05 Cr | ₹202.56 Cr | ₹147.75 Cr | ₹187.08 Cr | ₹187.75 Cr | ₹168.62 Cr | ₹162.85 Cr | ₹160.37 Cr | ₹143.14 Cr | ₹142.56 Cr | ₹134.94 Cr |
| Cost of Materials Consumed | ₹83.36 Cr | ₹77.3 Cr | ₹60.68 Cr | ₹43.78 Cr | ₹101.53 Cr | ₹13.6 Cr | ₹61.58 Cr | ₹55.73 Cr | ₹48.36 Cr | ₹44.84 Cr | ₹50.7 Cr | ₹47.53 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | ₹21.97 Cr | -₹16.1 Cr | -₹4.95 Cr | -₹12 Cr | -₹46.71 Cr | ₹48.18 Cr | -₹15.61 Cr | -₹7.13 Cr | ₹9.91 Cr | ₹9.78 Cr | ₹10.94 Cr | -₹30.8 Lakh |
| Employee Benefit Expense | ₹24.82 Cr | ₹24.69 Cr | ₹24.48 Cr | ₹22.69 Cr | ₹20.98 Cr | ₹19.77 Cr | ₹19.69 Cr | ₹20.08 Cr | ₹17.14 Cr | ₹17.56 Cr | ₹17.5 Cr | ₹15.43 Cr |
| Finance Costs | ₹46.8 Lakh | ₹49.4 Lakh | ₹41.5 Lakh | ₹51.2 Lakh | ₹41.7 Lakh | ₹50.65 Lakh | ₹42.7 Lakh | ₹33.5 Lakh | ₹60.1 Lakh | ₹49.4 Lakh | ₹46 Lakh | ₹81.6 Lakh |
| Depreciation & Amortisation | ₹8.5 Cr | ₹6.82 Cr | ₹6.64 Cr | ₹6.45 Cr | ₹6.08 Cr | ₹4.96 Cr | ₹4.74 Cr | ₹4.66 Cr | ₹3.91 Cr | ₹3.96 Cr | ₹3.98 Cr | ₹3.96 Cr |
| Other Expenses | ₹48.77 Cr | ₹48.46 Cr | ₹46.98 Cr | ₹38.91 Cr | ₹40.72 Cr | ₹38.14 Cr | ₹35.73 Cr | ₹29.4 Cr | ₹27.27 Cr | ₹26.4 Cr | ₹29.2 Cr | ₹24.88 Cr |
| Total Expenses | ₹187.88 Cr | ₹141.67 Cr | ₹134.24 Cr | ₹100.34 Cr | ₹123.02 Cr | ₹125.17 Cr | ₹106.56 Cr | ₹103.08 Cr | ₹107.19 Cr | ₹103.04 Cr | ₹112.78 Cr | ₹92.3 Cr |
| Profit Before Exceptional Items & Tax | ₹92.13 Cr | ₹67.38 Cr | ₹68.32 Cr | ₹47.41 Cr | ₹64.06 Cr | ₹62.58 Cr | ₹62.06 Cr | ₹59.78 Cr | ₹53.17 Cr | ₹40.1 Cr | ₹29.78 Cr | ₹42.64 Cr |
| Exceptional Items | ₹0 | -₹45.8 Lakh | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹92.13 Cr | ₹66.92 Cr | ₹68.32 Cr | ₹47.41 Cr | ₹64.06 Cr | ₹62.58 Cr | ₹62.06 Cr | ₹59.78 Cr | ₹53.17 Cr | ₹40.1 Cr | ₹29.78 Cr | ₹42.64 Cr |
| Total Tax Expense | ₹17.9 Cr | ₹17.25 Cr | ₹17.89 Cr | ₹12.62 Cr | ₹13.68 Cr | ₹15.8 Cr | ₹15.92 Cr | ₹15.13 Cr | ₹16.24 Cr | ₹10.31 Cr | ₹5.89 Cr | ₹14.13 Cr |
| Net Profit | ₹74.23 Cr | ₹49.68 Cr | ₹50.43 Cr | ₹34.79 Cr | ₹50.38 Cr | ₹46.78 Cr | ₹46.15 Cr | ₹44.64 Cr | ₹36.93 Cr | ₹29.79 Cr | ₹23.88 Cr | ₹28.51 Cr |
| Other Comprehensive Income | ₹4.1 Lakh | ₹4 Lakh | ₹3.4 Lakh | -₹21.5 Lakh | ₹8.7 Lakh | ₹6.04 Lakh | -₹21.7 Lakh | -₹5.5 Lakh | ₹5.6 Lakh | ₹27 Lakh | -₹13.8 Lakh | -₹1.46 Cr |
| Total Comprehensive Income | ₹74.27 Cr | ₹49.72 Cr | ₹50.46 Cr | ₹34.58 Cr | ₹50.47 Cr | ₹46.84 Cr | ₹45.93 Cr | ₹44.59 Cr | ₹36.99 Cr | ₹30.06 Cr | ₹23.75 Cr | ₹27.06 Cr |
| EBITDA (computed) | ₹101.1 Cr | ₹74.69 Cr | ₹75.37 Cr | ₹54.38 Cr | ₹70.56 Cr | ₹68.05 Cr | ₹67.24 Cr | ₹64.77 Cr | ₹57.69 Cr | ₹44.55 Cr | ₹34.22 Cr | ₹47.41 Cr |
| Basic EPS | ₹9.22 | ₹6.17 | ₹6.27 | ₹4.32 | ₹6.29 | ₹5.82 | ₹5.71 | ₹5.54 | ₹4.59 | ₹3.70 | ₹2.97 | ₹3.54 |
| Diluted EPS | ₹9.22 | ₹6.17 | ₹6.27 | ₹4.32 | ₹6.29 | ₹5.82 | ₹5.71 | ₹5.54 | ₹4.59 | ₹3.70 | ₹2.97 | ₹3.54 |
Shareholding Pattern of Supriya Lifescience Limited
As per the shareholding pattern filed with NSE for the quarter ended Mar 2026, promoters hold 68.30%, foreign institutional investors hold 5.16%, domestic institutional investors hold 5.70%, retail and other public shareholders hold 20.84% of Supriya Lifescience Limited. The company had 81,161 shareholders on record.
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Promoters | 68.30% | 68.30% | 68.30% | 68.30% | 68.30% | 68.30% |
| Public | 31.70% | 31.70% | 31.70% | 31.70% | 31.70% | 31.70% |
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | |
|---|---|---|---|---|---|
| Promoters | 68.30% | 68.30% | 68.30% | 68.28% | 68.24% |
| Public | 31.70% | 31.70% | 31.70% | 31.72% | 31.76% |
| Promoter change (YoY, %pts) | +0.00 | +0.00 | +0.02 | +0.04 | - |
Board & Governance of Supriya Lifescience Limited
As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Supriya Lifescience Limited has 12 directors - 7 independent and 5 executive. The board is chaired by Satish Waman Wagh.
| Director | Position | On board since | Listed boards |
|---|---|---|---|
| Satish Waman Wagh | Executive Director · Chairperson | 2008-03-26 | 1 |
| Smita Satish Wagh | Executive Director | 2008-03-26 | 1 |
| Saloni Satish Wagh | Executive Director · MD | 2019-07-01 | 1 |
| Shivani Satish Wagh | Executive Director · MD | 2019-07-01 | 1 |
| Balasaheb Gulabrao Sawant | Executive Director | 2023-05-26 | 1 |
| Dileep Kumar Jain | Non-Executive - Independent Director | 2021-03-25 | 4 |
| Dinesh Navnitlal Modi | Non-Executive - Independent Director | 2021-03-25 | 1 |
| Neelam Yashpal Arora | Non-Executive - Independent Director | 2021-03-25 | 3 |
| Ganapati Dadasaheb Yadav | Non-Executive - Independent Director | 2025-01-24 | 5 |
| Sunil Subhash Bhagwat | Non-Executive - Independent Director | 2025-01-24 | 1 |
| Manish Ishwarlal Panchal | Non-Executive - Independent Director | 2026-02-09 | 2 |
| Kothandaraman Hari | Non-Executive - Independent Director | 2026-02-09 | 2 |
| Committee | Members |
|---|---|
| Audit Committee | Dinesh Navnitlal Modi (Chairperson), Ganapati Dadasaheb Yadav, Satish Waman Wagh, Kothandaraman Hari (Chairperson), Manish Ishwarlal Panchal |
| Nomination and remuneration committee | Dinesh Navnitlal Modi (Chairperson), Sunil Subhash Bhagwat, Dileep Kumar Jain, Manish Ishwarlal Panchal, Kothandaraman Hari (Chairperson) |
| Stakeholders Relationship Committee | Dileep Kumar Jain (Chairperson), Satish Waman Wagh, Saloni Satish Wagh, Manish Ishwarlal Panchal (Chairperson) |
| Risk Management Committee | Satish Waman Wagh (Chairperson), Saloni Satish Wagh, Ganapati Dadasaheb Yadav |
| Corporate Social Responsibility Committee | Satish Waman Wagh (Chairperson), Saloni Satish Wagh, Sunil Subhash Bhagwat |
Charges & Borrowings of Supriya Lifescience Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 26 Jun 2025 | Idbi Trusteeship Services Limited | ₹114 Cr | Open |
| 03 May 2024 | Axis Bank Limited | ₹44 Cr | Open |
| 17 Apr 2024 | Others | ₹30 Cr | Open |
| 05 Jul 2012 | The Saraswat Cooperative Bank Ltd | ₹2 Cr | Open |
| 27 Jun 2009 | The Saraswat Cooperative Bank Ltd | ₹10.91 Cr | Open |
Total charge records: 45 View all charges
Employees and EPFO Compliance at Supriya Lifescience Limited
Supriya Lifescience Limited has a workforce of 450 employees as of Apr 04, 2025.
Employee and EPFO history for Supriya Lifescience Limited
Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
GST Compliance of Supriya Lifescience Limited
GST registrations and filing compliance for Supriya Lifescience Limited
State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
Credit Ratings, Litigation & Regulatory Alerts for Supriya Lifescience Limited
Credit ratings, litigation, and regulatory alerts for Supriya Lifescience Limited
Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Supriya Lifescience Limited
MSME payment history for Supriya Lifescience Limited
Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Supriya Lifescience Limited
Corporate group structure for Supriya Lifescience Limited
Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Supriya Lifescience Limited
MCA filings and documents for Supriya Lifescience Limited
Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Recent Activity on Supriya Lifescience Limited
Recent News on Supriya Lifescience Limited
Frequently Asked Questions about Supriya Lifescience Limited
Supriya Lifescience Limited is an active public limited company in the pharma sector based in Mumbai, Maharashtra, India. It was incorporated on 26 March 2008 (18+ years old) and is registered under CIN L51900MH2008PLC180452. Listed on BSE: 543434 and NSE: SUPRIYA. The company has 450 employees.
Supriya Lifescience Limited reported revenue of ₹827.88 Cr for FY 2026 (up 18.86% YoY) based on standalone NSE filings.
The current directors of Supriya Lifescience Limited are:
- Smita Satish Wagh - Whole-Time Director
- Neelam Yashpal Arora - Director
- Balasaheb Gulabrao Sawant - Whole-Time Director
- Satish Waman Wagh - Whole-Time Director
- Saloni Satish Wagh - Managing Director
- Shivani Satish Wagh - Managing Director
- Ganapati Dadasaheb Yadav - Additional Director
- Sunil Subhash Bhagwat - Additional Director
- Manish Ishwarlal Panchal - Additional Director
- Kothandaraman Hari - Additional Director
The primary industry of Supriya Lifescience Limited is pharma. The company specifically operates in api manufacturers. The company is currently active in this sector.
Yes. Supriya Lifescience Limited is listed on both BSE (code: 543434) and NSE (symbol: SUPRIYA).
Supriya Lifescience Limited can be reached at the registered office: 207208 Udyog Bhavan Sonawala Road Goregaon East, Mumbai, Maharashtra, India – 400063, or through the website supriyalifescience.com.